{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:08:42Z","timestamp":1790186922905,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-62260-5","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T15:51:48Z","timestamp":1753717908000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The oncolytic adenovirus Ad-TD-nsIL12 in primary or progressive pediatric IDH wild-type diffuse intrinsic pontine glioma results of two phase I clinical trials"],"prefix":"10.1038","volume":"16","author":[{"given":"Xiao","family":"Qian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihai","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2380-0900","authenticated-orcid":false,"given":"Louisa Chard","family":"Dunmall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hardev S.","family":"Pandha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanjie","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuduo","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanming","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyu","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingshan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2367-6313","authenticated-orcid":false,"given":"Yaohe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9626-7900","authenticated-orcid":false,"given":"Shengdian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4508-7678","authenticated-orcid":false,"given":"Hongwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"62260_CR1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/neuonc\/noy145","volume":"21","author":"NAP Lieberman","year":"2018","unstructured":"Lieberman, N. A. P. et al. Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy. Neuro-Oncol. 21, 83\u201394 (2018).","journal-title":"Neuro-Oncol."},{"key":"62260_CR2","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s00401-014-1307-x","volume":"128","author":"V Caretti","year":"2014","unstructured":"Caretti, V. et al. Subventricular spread of diffuse intrinsic pontine glioma. Acta Neuropathol. 128, 605\u2013607 (2014).","journal-title":"Acta Neuropathol."},{"key":"62260_CR3","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/neuonc\/nox107","volume":"19","author":"T Cooney","year":"2017","unstructured":"Cooney, T. et al. Contemporary survival endpoints: an International Diffuse Intrinsic Pontine Glioma Registry study. Neuro Oncol. 19, 1279\u20131280 (2017).","journal-title":"Neuro Oncol."},{"key":"62260_CR4","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1101\/gad.217778.113","volume":"27","author":"KM Chan","year":"2013","unstructured":"Chan, K. M. et al. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev. 27, 985\u2013990 (2013).","journal-title":"Genes Dev."},{"key":"62260_CR5","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis, D. N. et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 23, 1231\u20131251 (2021).","journal-title":"Neuro Oncol."},{"key":"62260_CR6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/neuonc\/noy145","volume":"21","author":"NAP Lieberman","year":"2019","unstructured":"Lieberman, N. A. P. et al. Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy. Neuro Oncol. 21, 83\u201394 (2019).","journal-title":"Neuro Oncol."},{"key":"62260_CR7","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41573-019-0029-0","volume":"18","author":"K Harrington","year":"2019","unstructured":"Harrington, K., Freeman, D. J., Kelly, B., Harper, J. & Soria, J. C. Optimizing oncolytic virotherapy in cancer treatment. Nat. Rev. Drug Discov. 18, 689\u2013706 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"62260_CR8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3389\/fonc.2018.00127","volume":"8","author":"D Benitez-Ribas","year":"2018","unstructured":"Benitez-Ribas, D. et al. Immune response generated with the administration of autologous dendritic cells pulsed with an allogenic tumoral cell-lines lysate in patients with newly diagnosed diffuse intrinsic pontine glioma. Front Oncol. 8, 127 (2018).","journal-title":"Front Oncol."},{"key":"62260_CR9","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1158\/0008-5472.CAN-14-0008","volume":"74","author":"M Esmaeili","year":"2014","unstructured":"Esmaeili, M. et al. IDH1 R132H mutation generates a distinct phospholipid metabolite profile in glioma. Cancer Res. 74, 4898\u20134907 (2014).","journal-title":"Cancer Res."},{"key":"62260_CR10","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1056\/NEJMoa2202028","volume":"386","author":"J G\u00e1llego P\u00e9rez-Larraya","year":"2022","unstructured":"G\u00e1llego P\u00e9rez-Larraya, J. et al. Oncolytic DNX-2401 virus for pediatric diffuse intrinsic pontine glioma. N. Engl. J. Med. 386, 2471\u20132481 (2022).","journal-title":"N. Engl. J. Med."},{"key":"62260_CR11","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.3390\/cells9112438","volume":"9","author":"Z Zhang","year":"2020","unstructured":"Zhang, Z. et al. A tumor-targeted replicating oncolytic adenovirus Ad-TD-nsIL12 as a promising therapeutic agent for human esophageal squamous cell carcinoma. Cells 9, 2438 (2020).","journal-title":"Cells"},{"key":"62260_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01385-8","volume":"8","author":"P Wang","year":"2017","unstructured":"Wang, P. et al. Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent. Nat. Commun. 8, 1395 (2017).","journal-title":"Nat. Commun."},{"key":"62260_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.122254","volume":"336","author":"S Li","year":"2024","unstructured":"Li, S. et al. Oncolytic virus Ad-TD-nsIL-12 inhibits glioma growth and reprograms the tumor immune microenvironment. Life Sci. 336, 122254 (2024).","journal-title":"Life Sci."},{"key":"62260_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53041-7","volume":"15","author":"W Ning","year":"2024","unstructured":"Ning, W. et al. Non-secreting IL12 expressing oncolytic adenovirus Ad-TD-nsIL12 in recurrent high-grade glioma: a phase I trial. Nat. Commun. 15, 9299 (2024).","journal-title":"Nat. Commun."},{"key":"62260_CR15","doi-asserted-by":"crossref","unstructured":"Pedretti, L. et al. Role of nutrition in pediatric patients with cancer. Nutrients 15, 710 (2023).","DOI":"10.3390\/nu15030710"},{"key":"62260_CR16","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa2024947","volume":"384","author":"GK Friedman","year":"2021","unstructured":"Friedman, G. K. et al. Oncolytic HSV-1 G207 immunovirotherapy for pediatric high-grade gliomas. N. Engl. J. Med. 384, 1613\u20131622 (2021).","journal-title":"N. Engl. J. Med"},{"key":"62260_CR17","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1158\/1078-0432.CCR-20-1499","volume":"27","author":"MI Chastkofsky","year":"2021","unstructured":"Chastkofsky, M. I. et al. Mesenchymal stem cells successfully deliver oncolytic virotherapy to diffuse intrinsic pontine glioma. Clin. Cancer Res. 27, 1766\u20131777 (2021).","journal-title":"Clin. Cancer Res."},{"key":"62260_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10043-0","volume":"10","author":"N Mart\u00ednez-V\u00e9lez","year":"2019","unstructured":"Mart\u00ednez-V\u00e9lez, N. et al. The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models. Nat. Commun. 10, 2235 (2019).","journal-title":"Nat. Commun."},{"key":"62260_CR19","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00262-014-1523-1","volume":"63","author":"W Lasek","year":"2014","unstructured":"Lasek, W., Zago\u017cd\u017con, R. & Jakobisiak, M. Interleukin 12: still a promising candidate for tumor immunotherapy?. Cancer Immunol. Immunother. 63, 419\u2013435 (2014).","journal-title":"Cancer Immunol. Immunother."},{"key":"62260_CR20","doi-asserted-by":"publisher","first-page":"eaaw5680","DOI":"10.1126\/scitranslmed.aaw5680","volume":"11","author":"EA Chiocca","year":"2019","unstructured":"Chiocca, E. A. et al. Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: results of a phase 1 trial. Sci. Transl. Med 11, eaaw5680 (2019).","journal-title":"Sci. Transl. Med"},{"key":"62260_CR21","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1093\/neuonc\/noab271","volume":"24","author":"EA Chiocca","year":"2022","unstructured":"Chiocca, E. A. et al. Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: An open-label, multi-institutional phase I trial. Neuro Oncol. 24, 951\u2013963 (2022).","journal-title":"Neuro Oncol."},{"key":"62260_CR22","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/ni.2959","volume":"15","author":"B Malissen","year":"2014","unstructured":"Malissen, B., Gr\u00e9goire, C., Malissen, M. & Roncagalli, R. Integrative biology of T cell activation. Nat. Immunol. 15, 790\u2013797 (2014).","journal-title":"Nat. Immunol."},{"key":"62260_CR23","doi-asserted-by":"publisher","first-page":"1201500","DOI":"10.3389\/fonc.2023.1201500","volume":"13","author":"H Paganetti","year":"2023","unstructured":"Paganetti, H. A review on lymphocyte radiosensitivity and its impact on radiotherapy. Front. Oncol. 13, 1201500 (2023).","journal-title":"Front. Oncol."},{"key":"62260_CR24","doi-asserted-by":"publisher","first-page":"e9342","DOI":"10.15252\/emmm.201809342","volume":"10","author":"KI Jones","year":"2018","unstructured":"Jones, K. I. et al. Radiation combined with macrophage depletion promotes adaptive immunity and potentiates checkpoint blockade. EMBO Mol. Med. 10, e9342 (2018).","journal-title":"EMBO Mol. Med."},{"key":"62260_CR25","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1002\/stem.3391","volume":"39","author":"M R\u00fcckert","year":"2021","unstructured":"R\u00fcckert, M., Flohr, A. S., Hecht, M. & Gaipl, U. S. Radiotherapy and the immune system: more than just immune suppression. Stem Cells 39, 1155\u20131165 (2021).","journal-title":"Stem Cells"},{"key":"62260_CR26","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.3390\/cancers16101811","volume":"16","author":"M Sue","year":"2024","unstructured":"Sue, M., Takeuchi, Y., Hirata, S., Takaki, A. & Otsuka, M. Impact of nutritional status on neutrophil-to-lymphocyte ratio as a predictor of efficacy and adverse events of immune check-point inhibitors. Cancers (Basel) 16, 1811 (2024).","journal-title":"Cancers (Basel)"},{"key":"62260_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101751","volume":"5","author":"K Liu","year":"2024","unstructured":"Liu, K. et al. Thymosin \u03b11 reverses oncolytic adenovirus-induced M2 polarization of macrophages to improve antitumor immunity and therapeutic efficacy. Cell Rep. Med. 5, 101751 (2024).","journal-title":"Cell Rep. Med."},{"key":"62260_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03285-0","volume":"11","author":"Y Liu","year":"2020","unstructured":"Liu, Y. et al. Intravenous injection of the oncolytic virus M1 awakens antitumor T cells and overcomes resistance to checkpoint blockade. Cell Death Dis. 11, 1062 (2020).","journal-title":"Cell Death Dis."},{"key":"62260_CR29","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1016\/S1470-2045(20)30173-X","volume":"21","author":"C Erker","year":"2020","unstructured":"Erker, C. et al. Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncol. 21, e317\u2013e329 (2020).","journal-title":"Lancet Oncol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62260-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62260-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62260-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T05:52:26Z","timestamp":1757310746000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62260-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["62260"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-62260-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"4 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yaohe Wang is an inventor of the patent of Ad-TD-nsIL12 (Modified interleukin 12 and its use in manufacture of a medicament for treatment of tumors, PCT\/CN2016\/098527). All other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6934"}}